News|Articles|November 18, 2026

Aficamten Reduces LV Mass, Wall Thickness in Nonobstructive HCM

Fact checked by: Maggie L. Shaw
Listen
0:00 / 0:00

Key Takeaways

  • Prespecified CMR substudy showed significant LV mass index and wall thickness reductions at week 36, primarily from decreased myocardial cellular mass without significant extracellular matrix or fibrosis changes.
  • NT-proBNP and high-sensitivity troponin I reductions correlated with structural remodeling, supporting mechanistic linkage between myosin inhibition and decreased wall stress/injury in nHCM.
SHOW MORE

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

Aficamten (Myqorzo; Cytokinetics) reduced left ventricular mass and wall thickness in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) at 36 weeks, according to new ACACIA-HCM NCT06081894) trial analyses presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, held in collaboration with the American Heart Association Scientific Sessions 2026 in Chicago.1

The data arrive as Cytokinetics plans to submit a supplemental new drug application to the FDA for aficamten in nHCM in the fourth quarter of 2026. The FDA approved the cardiac myosin inhibitor in December 2025 for adults with symptomatic obstructive HCM (oHCM).2 No therapy is currently approved for the nonobstructive form of the disease.

Imaging Points to Reduced Myocardial Cell Mass

In the prespecified cardiac magnetic resonance substudy, aficamten reduced left ventricular mass index and wall thickness compared with placebo at 36 weeks (both P < .001).1 The reduction in left ventricular mass index was driven by a decrease in myocardial cellular mass, with no significant changes in extracellular matrix or fibrosis measures. Reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin I correlated with the structural changes.

“The advanced imaging data provide crucial insights into favorable cardiac remodeling, showing that aficamten may reduce key structural markers of the disease,” said Stephen Heitner, MD, chief medical officer, Cytokinetics, in a statement.

A second abstract assessed patient-reported health status. At week 36, aficamten improved Kansas City Cardiomyopathy Questionnaire Overall Summary Score by 4.0 points more than placebo. Improvement beyond clinically relevant thresholds occurred in 33.7% of patients receiving aficamten vs 22.5% receiving placebo, and deterioration occurred in 7.4% vs 13.3%. The between-group difference widened through week 72, the company reported, and the effects faded within 4 weeks of treatment withdrawal.

A poster from the FOREST-HCM (NCT04848506) open-label extension trial tracked 410 patients with oHCM on long-term aficamten. Twelve patients (2.9%) developed a left ventricular ejection fraction (LVEF) below 50%, a rate of 2.1 events per 100 patient-years. No patients had an LVEF below 40%, and no heart failure hospitalizations or deaths were linked to systolic dysfunction.

Primary Trial Met Both End Points

The primary ACACIA-HCM results, published in The New England Journal of Medicine, randomly assigned 258 patients to aficamten and 259 to placebo.3 At 36 weeks, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) improved by 11.4 points with aficamten and 8.4 points with placebo (least squares mean difference, 3.0; 95% CI, 0.5-5.5; P = .021). Peak oxygen uptake increased by 0.64 mL/kg/min with aficamten and was essentially unchanged with placebo (−0.03 mL/kg/min; difference, 0.67 mL/kg/min; 95% CI, 0.2-1.1; P = .003).

The LVEF fell below 50% in 10.5% of patients receiving aficamten vs 0.8% receiving placebo. Serious adverse events occurred in 20.2% vs 14.7%, respectively.

A 5-domain responder analysis published in Circulation found that more patients receiving aficamten had symptom (71% vs 53%), NT-proBNP (63% vs 5%), septal e′ velocity (a marker of diastolic function; 51% vs 26%), and left atrial volume index (31% vs 23%) improvements.4 The difference in peak oxygen uptake response (45% vs 37%) was not statistically significant. Overall, 53% of patients receiving aficamten responded on at least 3 of the 5 domains compared with 14% receiving placebo.

“In patients with nHCM, aficamten was associated with improvements across a broad range of clinically relevant measures, including symptom burden and diastolic function,” wrote the researchers of the study. “These results underscore a potential benefit of aficamten in the population of patients with nHCM.”

References

  1. Cytokinetics announces additional data related to aficamten presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions held in collaboration with the American Heart Association Scientific Sessions 2026. News release. Cytokinetics. November 9, 2026. Accessed November 17, 2026. https://s206.q4cdn.com/793207125/files/doc_news/Cytokinetics-Announces-Additional-Data-Related-to-Aficamten-Presented-at-the-Hypertrophic-Cardiomyopathy-Medical-Society-HCMS-Scienti-O0F3S.pdf
  2. Aficamten improves health status, exercise capacity in challenging nonobstructive HCM. Healio. August 28, 2026. Accessed November 17, 2026. https://www.healio.com/news/cardiology/20260828/aficamten-improves-health-status-exercise-capacity-in-challenging-nonobstructive-hcm
  3. Masri A, Maron MS, Bhatia A, et al. Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med. Published online August 28, 2026. doi:10.1056/NEJMoa2603021
  4. Maron MS, Masri A, Bhatia A, et al. Global efficacy of aficamten in nonobstructive hypertrophic cardiomyopathy: results from ACACIA-HCM. Circulation. 2026;154(16):1547-1559. doi:10.1161/CIRCULATIONAHA.126.082026

Related to this article